Differences in outcomes between cholecalciferol and ergocalciferol supplementation in veterans with inflammatory bowel disease

Geriatrics and Gerontology International

Volumn 12, Issue 3, 2012, Pages 475-480

  Youssef, Dima ^a   Bailey, Beth ^a   Atia, Antwan ^a   El Abbassi, Adel ^b   Manning, Todd ^b   Peiris, Alan N ^a,b  

^a East Tennessee State University   (United States)

^b James H Quillen VA Medical Center   (United States)

Author keywords

Cholecalciferol; Crohn's disease; Ergocalciferol; Inflammatory bowel disease; Ulcerative colitis; VitaminD

Indexed keywords

25 HYDROXYVITAMIN D; COLECALCIFEROL; ERGOCALCIFEROL;

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ULCERATIVE COLITIS; VETERAN; VITAMIN SUPPLEMENTATION;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; CHOLECALCIFEROL; ERGOCALCIFEROLS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SOUTHEASTERN UNITED STATES; TREATMENT OUTCOME; VETERANS; VITAMIN D DEFICIENCY;

EID: 84862637208     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2011.00798.x     Document Type: Article

References (27)

1. Peiris AN, Bailey BA, Manning T. The relationship of vitamin D deficiency to health care costs in veterans. Mil Med 2008; 173: 1214-1218.
2. Gibson T, Ozminkowski R, Wang S, Burton W, Goetzel R, Maclean T. The direct cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med 2008; 50: 1261-1272.
3. Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J Intern Med 1993; 239: 131-137.
4. Soren PG, Jorgensen CL, Hvas JA etal. Vitamin D deficiency in active Crohn's disease. Gastroenterology 2008; 134: A668; Abstract W1266.
5. Cantorna MT. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog Biophys Mol Biol 2006; 92: 6-64.
6. Cantorna MT. 1. 25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000; 130: 2648-2652.
7. Frioicu M, Weaver V, Wynn T, McDowell M, Welsh J, Cantorna M. A crucial role for the vitamin D receptor in vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol 2003; 17: 2386-2392.
8. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004; 89: 5387-5391.
9. International Classification of Diseases, 9th Revision. Clinical Modifications. Geneva: World Health Organization, 2010.
10. Atia A, Murthi R, Bailey B etal. Vitamin D status in veterans with inflammatory bowel disease: relationship to health care costs and service. Mil Med 2011; 176: 711-714.
11. Peiris AN, Bailey BA, Manning T, Adebonojo L. Are 25-hydroxyvitamin D levels adequately monitored following evidence of vitamin D insufficiency in veterans? Mil Med 2010; 175: 453-456.
12. Emkey RD, Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 2006; 119: S18-S24.
13. Hooper M, Faustino A, Reid IR etal. Randomized, active-controlled study of once-weekly alendronate 280mg high dose oral buffered solution for treatment of Paget's disease. Osteoporos Int 2009; 20: 141-150.
14. Ettinger MP, Gallagher R, MacCosbe PE. Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract 2006; 12: 522-528.
15. Chel V, Wijnhoven HA, Smit JH, Ooms M, Lips P. Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents. Osteoporos Int 2008; 19: 663-671.
16. Sanders KM, Stuart AL, Williamson EJ etal. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010; 303: 1815-1822.
17. Romagnoli E, Mascia ML, Cipriani C etal. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J Clin Endocrinol Metab 2008; 93: 3015-3020.
18. Khazai NB, Judd SE, Jeng L etal. Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol, and UV light. J Clin Endocrinol Metab 2009; 94: 2037-2043.
19. Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr 2006; 84: 694-697.
20. Heaney RP, Recker RR, Grote J, Horst RL, Armas LA. Vitamin D(3) is more potent than vitamin D(2) in humans. J Clin Endocrinol Metab 2011; 96: E447-E452.
21. Leventis P, Kiely PD. The tolerability and biochemical effects of high-dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency. Scand J Rheumatol 2009; 38: 149-153.
22. Ross AC, Manson JE, Abrams SA etal. The 2011 Report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96: 53-58.
23. Grant WB. In defense of the sun: an estimate of changes in mortality rates in the United States if mean serum 25-hydroxyvitamin D levels were raised to 45ng/mL by solar ultraviolet-B irradiance. Dermato-Endocrinology 2009; 1: 207-214.
24. Burton JM, Kimball S, Vieth R etal. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010; 74: 1852-1859.
25. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008; 88: 582S-586S.
26. Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL. Vitamin D supplementation during pregnancy: double blind, randomized clinical trial of safety and effectiveness. J Bone Miner Res 2011; 26: 2341-2357.
27. Youssef DA, El Abbassi AM, Cutchins DC, Chhabra S, Peiris AN. Vitamin D deficiency: implications for acute care in the elderly and in patients with chronic illness. Geriatr Gerontol Int 2011; 11: 395-407.